Abstracts

Citation

Modeling of Actual Randomization Values: Filling A Gap in the Current SDTM Foundational Standards. Presented at: CDISC US Interchange.

Citation

Grant Campbell, Stephen A. Spector, M.D. 1,25-dihydroxycholecalciferol Triggers Autophagy in Human Macrophages That Inhibits Productive HIV-1 Infection. Presented at: 17th Conference on Retroviruses & Opportunistic Infections.

Citation

Maxensia Owor, Patricia DeMarrais, Kristin Baltrusaitis, Lisa M Frenkel, Brookie Best, Lynda Stranix Chibanda, Mac Mallewa, Portia Kamthunzi, Dhayendre Moodley, Avy Violari, Tsungai Chipato, Brenda Kakayi, Ramesh Bhosale, Mary Glenn Fowler. 1077BF: Breast Milk Reservoir, Tenofovir levels and HIV Transmission Among Breastfeeding Mothers. Presented at: CROI 2024; 2024 Mar 04.

Citation

Patricia M. Flynn, M.D., M.S., Sharon Appelbaum Nachman, M.D., Stephen A. Spector, M.D., Coleen K. Cunningham, M.D., Adriana Weinberg, M.D., Robert F. Pass, M.D., Petronella Muresan, M.S., Wende Levy, R.N., M.S., George K. Siberry, M.D., M.P.H., Edward Handelsman, M.D. 2009 Influenza A (H1N1) Immunization in HIV-1 Perinatally Infected Children and Youth. Presented at: 17th Conference on Retroviruses & Opportunistic Infections.

Citation

24 and 48 Week Results from IMPAACT P1066: Raltegravir (RAL) Granules for Suspension (GFS) Formulation in Infants 4 Weeks (wks) to 6 Months (mos) of age. Presented at: 20th Conference on Retroviruses and Opportunistic Infections.

Citation

Sharon Appelbaum Nachman, M.D., Pearl Samson, M.S., Lisa M. Frenkel, M.D., Edward P. Acosta, Pharm.D., Hedy Teppler, M.D., Terence Fenton, Ed.D., Edward Handelsman, M.D., Carol J. Worrell, M.D., Bobbie L. Graham, B.S., Andrew A. Wiznia, M.D. 24 Week Safety and efficacy from IMPAACT P1066: A Phase I/II, Multicenter, Open-Label, Noncomparative Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth. Presented at: 49th Intersci Conf on Antimicrobial Agents & Chemotherapy.

Citation

Jorge Lujan-Zilbermann, M.D. 28 and 72 week immunogenicity of one dose vs. two doses of Quadrivalent Meningococcal Conjugate Vaccine in HIV-infected Youth. Presented at: 17th Conference on Retroviruses & Opportunistic Infections.

Citation

28- and 72-week immunogenicity of one dose vs. two doses of Quadrivalent Meningococcal Conjugate Vaccine in HIV-infected Youth. Presented at: 17th Conference on Retroviruses & Opportunistic Infections.

Citation

John ( Jack ) Moye, Jr., M.D., E. Richard Stiehm, M.D., James Bethel, Ph.D., Helene M.A. Paxton, M.S., M.T., Hildie Suter, B.S., Susan Plaeger, Ph.D., Howard Max Rosenblatt, M.D., Alan Landay, Ph.D., Lynne M. Mofenson, M.D., F.A.A.P., Bonnie J. Mathieson, Ph.D., Jonathan Kagan, Ph.D. 3-Color Flow Cytometric Markers of Lymphocyte Activation and Memory in Perinatal HIV Transmission and Infant Infection.

Citation

A comparison of DNA and plasma trofile results in a treatment experienced study population prior to initiation of new antiretroviral regimens. Presented at: 2011 Int'l Workshop on HIV & Hepatitis Virus Drug Resistance & Curative Strategies,.